MUGA / Equilibrium Radionuclide Angiography⁹⁹ᵐTc-labeled red blood cells

Quick Answer

MUGA (equilibrium radionuclide angiography) measures left-ventricular ejection fraction (LVEF) with high accuracy and reproducibility by imaging Tc-99m-labeled red blood cells in the blood pool, gated to the ECG across the cardiac cycle. Its main modern use is serial monitoring of LVEF during cardiotoxic chemotherapy (anthracyclines, HER2-targeted agents), where reproducibility matters more than anatomic detail.

Definition & Role

MUGA is a count-based, geometry-independent measurement of ventricular function. Unlike echocardiography (geometric assumptions, operator-dependent) or gated SPECT (perfusion-linked), MUGA's strength is a highly reproducible EF number — so a small, real change across serial studies can be trusted, which is exactly what cardio-oncology surveillance needs.

Physiology / Principle

Because tracer is confined to the blood pool, LV counts are proportional to LV volume. Ejection fraction is derived from counts at end-diastole vs end-systole (background-corrected) — no geometric model required:

LVEF = (ED counts − ES counts) ÷ (ED counts − background) × 100

Method

• RBC labeling: in vitro (highest efficiency, least free pertechnetate), modified in vivo, or in vivo tagging with Tc-99m; a stannous (tin) pre-dose reduces pertechnetate inside RBCs so it binds hemoglobin.
• Gated planar acquisition in the LAO "best-septal" view (separates the ventricles), building a representative averaged cardiac cycle from many beats.
• LVEF computed from the count-based ED/ES ROI; regional wall motion assessed qualitatively.

Interpretation

Report the LVEF (and often regional wall motion). Serial comparison requires the same technique and lab. Normal resting LVEF is generally ≥ 50% (lab-defined). A defined absolute or relative EF drop triggers an oncology decision.

Cardiotoxicity Surveillance (Cardio-Oncology)

MUGA is a classic tool for detecting cancer-therapy-related cardiac dysfunction (CTRCD):

• A commonly used trigger is a fall in LVEF ≥ 10 percentage points to below the lower limit of normal (e.g. < 50–53%), prompting holding/modifying the cardiotoxic agent and cardioprotective therapy.
• Anthracyclines cause dose-dependent, often irreversible toxicity; trastuzumab (HER2) toxicity is typically reversible and dose-independent.
• Modern cardio-oncology increasingly uses echocardiographic global longitudinal strain (GLS) to detect subclinical dysfunction earlier, but MUGA remains valued where reproducibility or poor echo windows are decisive.

Reporting Checklist

• Report LVEF with the method and reference range; comment on regional wall motion.
• State labeling method and confirm adequate labeling (no free-pertechnetate signature).
• Note rhythm (arrhythmia degrades gating) and view adequacy (LAO best-septal).
• For surveillance, compare to prior using the same technique/lab and state the change against the oncology threshold.

Common Pitfalls

• Poor RBC labeling → free pertechnetate (thyroid/stomach/salivary activity), degrading counts and EF.
• Arrhythmia (atrial fibrillation, frequent ectopy) degrades gating and EF reliability.
• Overlapping chambers if the LAO "best-septal" view is not optimized.
• Comparing across different techniques/labs invalidating a trend.

Board Pearls

Board numbers at a glance:

MUGA-derived LVEF is count-based and geometry-independent, so it is highly reproducible — small, real changes across serial studies can be trusted. That reproducibility is exactly what cardiotoxicity surveillance (anthracyclines, HER2-targeted therapy) needs, where a defined EF drop triggers an oncology decision.

Accuracy depends on good RBC labeling (in-vitro highest efficiency, least free pertechnetate), a well-optimized LAO best-septal view, and stable rhythm — atrial fibrillation and frequent ectopy degrade gating and EF reliability.

A common CTRCD trigger is an LVEF fall ≥ 10 points to below the lower limit of normal. Anthracycline toxicity is dose-dependent and often irreversible; trastuzumab toxicity is typically reversible and dose-independent. Echo GLS now detects subclinical dysfunction earlier, but MUGA persists where reproducibility or poor echo windows matter.

Related Pages

• Tracer: Tc-99m-labeled RBC (labeling methods, free-pertechnetate pitfall).
• Related: Nuclear cardiology overview; pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A count-based EF schematic (ED vs ES counts, background ROI).
• The LAO best-septal view geometry separating the ventricles.
• A cardiotoxicity surveillance timeline with the EF-drop threshold.

Self-Check (Board-Style)